Clearside Biomedical Stock Performance
| CLSD Stock | USD 1.00 0.01 0.99% |
On a scale of 0 to 100, Clearside Biomedical holds a performance score of 5. The firm shows a Beta (market volatility) of 0.33, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Clearside Biomedical's returns are expected to increase less than the market. However, during the bear market, the loss of holding Clearside Biomedical is expected to be smaller as well. Please check Clearside Biomedical's potential upside, rate of daily change, and the relationship between the sortino ratio and skewness , to make a quick decision on whether Clearside Biomedical's price patterns will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Clearside Biomedical are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain basic indicators, Clearside Biomedical exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Acquisition by Lasezkay George M of 500000 shares of Clearside Biomedical at 0.97 subject to Rule 16b-3 | 01/08/2025 |
2 | Acquisition by Chong Ngai Hang Victor of 250000 shares of Clearside Biomedical at 0.97 subject to Rule 16b-3 | 01/10/2025 |
3 | Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare ... | 02/04/2025 |
4 | Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented ... | 02/10/2025 |
5 | Acquisition by Yerxa Benjamin R of 7813 shares of Clearside Biomedical at 1.31 subject to Rule 16b-3 | 02/14/2025 |
6 | Clearside Biomedicals Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS for Regulatory Review in China for the T... | 02/20/2025 |
7 | Acquisition by Thorp Clay of 15000 shares of Clearside Biomedical at 0.92 subject to Rule 16b-3 | 02/24/2025 |
8 | Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on ... | 03/06/2025 |
9 | Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide ... | 03/12/2025 |
10 | Acquisition by Whitmore Bradford T of 70812 shares of Clearside Biomedical at 0.7278 subject to Rule 16b-3 | 03/19/2025 |
11 | Clearside Biomedicals Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD Diabetic Eye Disease Summit | 03/20/2025 |
| Begin Period Cash Flow | 48.4 M |
Clearside |
Clearside Biomedical Relative Risk vs. Return Landscape
If you would invest 88.00 in Clearside Biomedical on December 23, 2024 and sell it today you would earn a total of 12.00 from holding Clearside Biomedical or generate 13.64% return on investment over 90 days. Clearside Biomedical is currently generating 0.2946% in daily expected returns and assumes 4.1984% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Clearside, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Clearside Biomedical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Clearside Biomedical's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Clearside Biomedical, and traders can use it to determine the average amount a Clearside Biomedical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0702
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CLSD | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.2 actual daily | 37 63% of assets are more volatile |
Expected Return
| 0.29 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Clearside Biomedical is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Clearside Biomedical by adding it to a well-diversified portfolio.
Clearside Biomedical Fundamentals Growth
Clearside Stock prices reflect investors' perceptions of the future prospects and financial health of Clearside Biomedical, and Clearside Biomedical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Clearside Stock performance.
| Return On Equity | -13.1 | ||||
| Return On Asset | -0.48 | ||||
| Operating Margin | (5.72) % | ||||
| Current Valuation | 53.8 M | ||||
| Shares Outstanding | 75.84 M | ||||
| Price To Earning | 130.00 X | ||||
| Price To Book | 3.93 X | ||||
| Price To Sales | 9.90 X | ||||
| Revenue | 8.23 M | ||||
| Gross Profit | 7.7 M | ||||
| EBITDA | (23.06 M) | ||||
| Net Income | (32.48 M) | ||||
| Cash And Equivalents | 29.03 M | ||||
| Cash Per Share | 0.48 X | ||||
| Total Debt | 43 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 5.56 X | ||||
| Book Value Per Share | (0.47) X | ||||
| Cash Flow From Operations | (18.14 M) | ||||
| Earnings Per Share | (0.45) X | ||||
| Market Capitalization | 76.22 M | ||||
| Total Asset | 34.02 M | ||||
| Retained Earnings | (320.92 M) | ||||
| Working Capital | 23.31 M | ||||
| Current Asset | 20.48 M | ||||
| Current Liabilities | 5.2 M | ||||
About Clearside Biomedical Performance
By analyzing Clearside Biomedical's fundamental ratios, stakeholders can gain valuable insights into Clearside Biomedical's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Clearside Biomedical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Clearside Biomedical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.7 K | 1.5 K | |
| Return On Tangible Assets | (0.86) | (0.90) | |
| Return On Capital Employed | (0.82) | (0.86) | |
| Return On Assets | (0.86) | (0.90) | |
| Return On Equity | 1.84 | 1.93 |
Things to note about Clearside Biomedical performance evaluation
Checking the ongoing alerts about Clearside Biomedical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Clearside Biomedical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Clearside Biomedical has some characteristics of a very speculative penny stock | |
| Clearside Biomedical had very high historical volatility over the last 90 days | |
| Clearside Biomedical has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 8.23 M. Net Loss for the year was (32.48 M) with profit before overhead, payroll, taxes, and interest of 7.7 M. | |
| Clearside Biomedical currently holds about 29.03 M in cash with (18.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.48. | |
| Clearside Biomedical has a frail financial position based on the latest SEC disclosures | |
| Latest headline from globenewswire.com: Clearside Biomedicals Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD Diabetic Eye Disease Summit |
- Analyzing Clearside Biomedical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Clearside Biomedical's stock is overvalued or undervalued compared to its peers.
- Examining Clearside Biomedical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Clearside Biomedical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Clearside Biomedical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Clearside Biomedical's stock. These opinions can provide insight into Clearside Biomedical's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Clearside Stock analysis
When running Clearside Biomedical's price analysis, check to measure Clearside Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearside Biomedical is operating at the current time. Most of Clearside Biomedical's value examination focuses on studying past and present price action to predict the probability of Clearside Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearside Biomedical's price. Additionally, you may evaluate how the addition of Clearside Biomedical to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |